Literature DB >> 9377724

Neurogenic factors and hypertension in chronic renal failure.

V M Campese1.   

Abstract

The association between hypertension and chronic renal disease is well recognized. Various factors may play a role in the pathogenesis of hypertension in chronic renal failure. Those include sodium retention and volume expansion, and increased activity of vasoconstrictors, such as the renin-angiotensin system. More recently, increased activity of the sympathetic nervous system has emerged as a leading factor in the pathogenesis of hypertension in these patients. We have used the model of 5/6 nephrectomized rats to study the role of the sympathetic nervous system in the pathogenesis of this form of hypertension. We have shown greater norepinephrine turnover rate in the posterior hypothalamic nuclei and locus coeruleus of CRF than control rats. Dorsal rhizotomy prevented the rise in blood pressure and the increase in NE turnover rate in the posterior hypothalamus and the locus coeruleus. An acute injury to the kidney produced by intrarenal injection of phenol, causes an immediate rise in blood pressure and in NE secretion from the posterior hypothalamus, that can be prevented by renal denervation. Dorsal rhizotomy prevented the development of hypertension in rats with chronic renal failure. The studies suggest that afferent impulses from the kidney to central integrative structures in the brain may be responsible for the rise in blood pressure in chronic renal failure.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9377724

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  14 in total

Review 1.  Renal afferents and hypertension.

Authors:  John Ciriello; Cleusa V R de Oliveira
Journal:  Curr Hypertens Rep       Date:  2002-04       Impact factor: 5.369

Review 2.  Renal sympathetic nerve ablation: the new frontier in the treatment of hypertension.

Authors:  Markus P Schlaich; Henry Krum; Paul A Sobotka
Journal:  Curr Hypertens Rep       Date:  2010-02       Impact factor: 5.369

Review 3.  New therapeutic approaches to resistant hypertension.

Authors:  Markus P Schlaich; Henry Krum; Murray D Esler
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

4.  Alpha(2A)-adrenoceptors regulate sympathetic transmitter release in mice kidneys.

Authors:  O Vonend; S Habbel; J Stegbauer; J Roth; L Hein; L C Rump
Journal:  Br J Pharmacol       Date:  2006-11-20       Impact factor: 8.739

Review 5.  Renal sympathetic denervation: applications in hypertension and beyond.

Authors:  Michael Böhm; Dominik Linz; Daniel Urban; Felix Mahfoud; Christian Ukena
Journal:  Nat Rev Cardiol       Date:  2013-06-18       Impact factor: 32.419

Review 6.  How does renal denervation lower blood pressure and when should this technique be considered for the treatment of hypertension?

Authors:  Kui Toh Gerard Leong; Henry Krum
Journal:  Curr Cardiol Rep       Date:  2013-11       Impact factor: 2.931

Review 7.  Renal denervation in human hypertension: mechanisms, current findings, and future prospects.

Authors:  Markus P Schlaich; Dagmara Hering; Paul A Sobotka; Henry Krum; Murray D Esler
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

8.  Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings.

Authors:  W Zhang; J L Li; M Hosaka; R Janz; J M Shelton; G M Albright; J A Richardson; T C Südhof; R G Victor
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

Review 9.  Renal denervation: a novel non-pharmacological approach in heart failure.

Authors:  Michael Böhm; Sebastian Ewen; Dominik Linz; Jan-C Reil; Stephan Schirmer; Christian Ukena; Felix Mahfoud
Journal:  J Cardiovasc Transl Res       Date:  2014-02-28       Impact factor: 4.132

Review 10.  The sympathetic nervous system in chronic kidney disease.

Authors:  Sebastian Ewen; Christian Ukena; Dominik Linz; Roland E Schmieder; Michael Böhm; Felix Mahfoud
Journal:  Curr Hypertens Rep       Date:  2013-08       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.